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oston, Massachusetts
ranslational research has delivered us with many proven or
otential biomarkers for evaluation and management of the
atient with heart disease, and unmistakably, biomarker
esting has absolutely contributed to the basic understand-
ng of many cardiovascular diseases. However—with rare
xception—most novel biomarkers with potential cardiovas-
ular applications have a long road to travel before they find
linical applicability.
See page 243
Indeed, over the past decade, among the plethora of novel
iomarkers described to have potential value for use in
ardiovascular disease states, most (although intellectually
ogical and with interesting biologic data to support their
se) have been found to be “not ready for prime time,”
requently with issues regarding the imperfect methods for
heir measurement, as well as uncertainty about their true
alue to the clinician. Thus, for new blood tests with
otential cardiac applications, getting “lost in translation”
uring the bench-to-bedside journey is an obvious risk.
The bridging of biologic plausibility to clinical practical-
ty is crucial for the survival of a biomarker during its
ench-to-bedside translation; in addition to the obvious
uestion as to whether a new marker is robust and easy to
easure in the clinical arena, important questions to con-
ider during this period include whether the test adds
eaningful information to what we already have from other,
ore established biomarkers; whether the test truly adds to
hat we already know about the underlying biology of the
atient in whom it is tested; and lastly, whether there is a
otential therapeutic imperative associated with the results
rom testing. In other words, does the marker help us do a
etter job of caring for our patients?
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †Division of Cardiology and ‡Section of Heart Failure, Massachusettst
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s supported in part by the Balson Clinical Scholar Fund.Looking to biomarkers that have withstood this “test,” as
n example, clinicians are well versed with the value of
ardiac troponin (cTn) in patients with acute myocardial
nfarction (AMI). Both cTnT and cTnI are superior to
reatine kinase-myocardial band for the diagnosis of AMI,
nd biologically, patients with acute coronary syndromes
nd elevated cTn concentrations more often have intracoro-
ary and microvascular thrombus or high-risk coronary
natomy and have worse outcomes. Lastly, just as would be
redicted by the biology that leads to cTn release, patients
ith elevated values of these markers appear to have
ncremental benefit from intravenous antiplatelet drugs or
arly invasive management compared to patients without
uch elevations.
Thus, cardiac biomarkers can—and do—play a role in the
ay we clinicians approach our patients; yet, this does not
hange the fact that most novel markers get lost along the
ay from scientific discovery to clinical application, often
ecause it is totally unclear where a new biomarker test truly
ts in.
It is in this setting that, in this issue of the Journal, Weir
t al. (1) add to the understanding of a novel biomarker
alled ST2. A peptide with a structural sequence that
dentifies it as an interleukin (IL)-receptor family member,
T2 exists both in membrane-bound form (ST2 ligand
ST2L]) as well as in a shed, truncated soluble form (soluble
T2 [sST2]) (2). Although described to play a role in
nflammation and tolerance (mediating function of
-helper cells), ST2 clearly has a cardiovascular role eluci-
ated with a classical “translational research” approach: in a
odel of myocyte stretch, the ST2 gene transcript was
ound to be dramatically up-regulated (3); furthermore, in
he context of left ventricular pressure and volume overload,
nterruption of the ST2 gene (or infusion of large amounts
f sST2) results in a deleterious phenotype marked by
nchecked myocardial hypertrophy, dilation of ventricular
hambers, and reduction in ejection fraction—essentially
he human equivalent of remodeling after AMI or severe
eart failure (HF) (4).
It is of note and of interest that the functional ligand for
T2 is IL-33, a cardiac fibroblast product, also produced in
esponse to stretch. IL-33 is known to mediate the negative
ffects of pressure and volume overload on ventricular
yocytes—infusion of this hormone prevents remodeling
hen the heart is acutely exposed to pressure overload, for
xample—and thus has a cardioprotective role in the setting
f myocyte stretch and injury (4). The current theory is that
ST2 plays a delicate role as a “decoy” receptor for IL-33;
oo much sST2 in the context of potential stretch-induced
njury to the heart may therefore result in inadequate
ardioprotection from IL-33, with a heightened risk for
emodeling, ventricular dysfunction, or death.
Clinically, as might be expected from this biological
ackground, among patients with HF, sST2 values appear
o associate with more prevalent cardiac structural abnor-
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ST2 and Remodeling After MI January 19, 2010:251–3alities on echocardiography, including a more dilated and
ysfunctional left and right ventricle, as well as elevated
lling pressures (5). Furthermore, and strikingly, concen-
rations of sST2 are powerfully prognostic (and additive to
atriuretic peptides for this purpose) among patients who
ave acutely destabilized HF, while in patients with AMI,
ST2 concentrations are similarly additive to cTns or
atriuretic peptides for predicting death or the development
f future HF (5–11).
Despite these interesting observational results, mechanisti-
ally, it remained yet unclear just what biologic process in vivo
ST2 might be predicting that so powerfully identified a risk
or future cardiovascular events—events not necessarily pre-
icted by our current biomarker armamentarium.
In the work by Weir et al. (1), further important answers
bout sST2 have been gained. In this relatively small but
mportant study of 100 subjects randomly assigned to
eceive eplerenone or placebo after AMI, sST2 values were
orrelated with multiple measures from cardiac magnetic
esonance imaging, including left ventricular ejection frac-
ion and left ventricular chamber size as well as MI volumes;
n addition, sST2 values were compared with other biomar-
ers, including measures of neurohormonal activation. The
uthors found that sST2 values at enrollment strongly
orrelated with greater infarct severity as well as the pres-
nce of microvascular obstruction, 2 very important predic-
ors of future adverse outcome for patients with MI. In
ddition, concentrations of sST2 correlated with both levels
f norepinephrine and aldosterone, but not with N-terminal
ro-brain natriuretic peptide (NT-proBNP). Importantly,
s each subject had serial magnetic resonance imaging scans,
he authors were also able to connect the fact that sST2
oncentrations at the time of enrollment were strongly
redictive of future infarct remodeling.
An interesting finding in the study by Weir et al. (1) was the
ost hoc observation that the antiremodeling benefits of
plerenone were mainly restricted to patients with a high sST2
oncentration at the time of enrollment. These findings are
dditive to those of Iraqi et al. (12), who found that treatment
ith eplerenone suppressed post-AMI collagen turnover.
aken together, these findings imply the potential opportunity to
se biomarkers to identify patients at highest risk for remodel-
ng—the very patients most likely to respond favorably to antire-
odeling therapies, such as aldosterone receptor blockade.
The importance of a biomarker to predict remodeling is not
nsignificant: remodeling after AMI or in chronic HF is a
ivotal step leading to worsened ventricular function and
eightened risk for death. Remodeling has no symptoms, the
iming of its occurrence is difficult to predict, and remodeling
annot be detected without imaging techniques such as mag-
etic resonance imaging or echocardiography. Given these
acts and the fact that remodeling is not necessarily a
niversal process among patients at risk for it, it is attractive
o consider the possibility of seeking remodeling in patients
sing markers of the biological processes that underlie it. In
his regard, several biomarkers have been examined for this fpplication, including matrix metalloproteinases, natriuretic
eptides, and inflammatory markers (Table 1), to name a
ew. We can now add sST2 to this list; to one degree or
nother, these markers appear to provide unique informa-
ion about the presence and significance of remodeling and
otentially provide a therapeutic target for remodeling—at a
ivotal step in HF development or progression
Although a small study and not designed a priori to
xamine the value of sST2 in remodeling, the study by Weir
t al. (1) does add some important mechanistic data to an
ncreasingly interesting story about sST2 in cardiac disease.
empering our enthusiasm for the results in the present
tudy, both NT-proBNP and, particularly, aldosterone ap-
eared to be associated with changes in ventricular structure
nd function over time, so it remains unclear whether sST2
as superior (or at least additive) to these markers for
redicting remodeling; given the absence of correlation
etween sST2 and NT-proBNP, and the relative lack of
hange in aldosterone concentration over time, it is tempt-
ng to think that sST2 measurement provided unique
nformation that was not reflected by either other marker.
Although excellent basic scientific data existed to support
he candidacy of sST2 measurement in patients, mechanis-
ic data were lacking in patients. Clinically, the data of Weir
t al. (1) help us to understand why sST2 measurement
ppears to convey important prognostic information (that is
dditive to markers such as natriuretic peptides) across
merican Heart Association stages B, C, and D; given the
mportance of remodeling on the early development of HF,
t would also obviously be tempting to speculate on the value
f sST2 for predicting future HF in patients at risk for it
so-called stage A HF). With the recent development of a
ighly sensitive sST2 assay (able to detect the protein in
ery small quantities among apparently-normal patients),
uch studies may now be performed.
As more studies are done to examine the role of sST2 in
eart disease onset, progression, and complication, this
arker seems increasingly important, and the journey of
ST2, “found in translation,” continues onward. The prog-
ostic value of sST2 is already established. If, as the study by
eir et al. (1) suggests, a therapeutic imperative could be
elected Biomarkersssociated With Ventricular Remodeling*Table 1 Select d Biomark rsAssociated With Ventricular Remodeling*
Natriuretic peptides
Troponins
Matrix metalloproteinases
Collagen turnover markers: type I collagen telopeptide
Tenascin C
Inflammatory markers: tumor necrosis factor receptors, C-reactive protein,
cardiotrophin-1
Fibrosis markers: osteopontin, soluble ST2
Neurohormonal markers: aldosterone, aldosterone/renin ratio, angiotensin II
Others: tissue plasminogen activator
List abbreviated for brevity.ound to reduce the risk for development or progression of
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January 19, 2010:251–3 ST2 and Remodeling After MIF associated with elevated sST2 values, that would be a
onsiderable advance.
Along these lines, we should consider, generally speaking,
here things are heading for the field of cardiac biomarker
esting: as we slowly move further toward a biologically-
uided era of management of our patients with heart
isease, biomarkers in cardiology must go from being
omething “nice to have” to something that we “need to
ave.” Rather than using markers to confirm something we
lready know about our patients (or to identify a bad
rognosis we can do nothing about), measuring concentra-
ions of a biomarker such as sST2 should not only tell us
omething that we would not have otherwise known at the
edside, but also identify an opportunity to better treat our
atients as a consequence.
eprint requests and correspondence: Dr. James L. Januzzi, Jr.,
assachusetts General Hospital, 32 Fruit Street, Yawkey 5984,
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